Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy.
Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy.
复制标题
肾细胞癌疫苗治疗在靶向治疗时代的作用。
DOI：
10.1111/iju.12147
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Uemura H.
中科院分区：
文献类型：
--
作者：
Yoshimura K;Uemura H.Yoshimura K;Uemura H.
肾细胞癌是最常见的起源于肾脏的恶性肿瘤。与其他实体瘤相比，它对传统的治疗方式，如化疗和放疗没有反应。然而，众所周知，肾细胞癌是最具免疫应答性的癌症之一，在肾细胞癌的治疗中，研究了几种免疫治疗策略，并取得了不同程度的成功。利用α干扰素或高剂量白细胞介素- 2进行免疫治疗的发展是最成熟的治疗方法，并且与持久的疾病控制有关。尽管肾细胞癌中缺乏明确的抗原阻碍了更特异性疫苗的开发，但30多年来，关于疫苗接种治疗的研究一直是治疗肾细胞癌的特别兴趣。目前，有三种基于细胞的疫苗用于肾癌的治疗：自体肿瘤细胞疫苗、转基因肿瘤疫苗和树突状细胞疫苗。另一种类型是基于肽的疫苗接种，以肿瘤相关抗原作为可能的靶点，如碳酸酐酶IX、生存素和端粒酶，这些抗原在肾细胞癌中过表达。在本文中，我们回顾了已完成的疫苗治疗临床试验的数据，并讨论了未来的试验，以评估在最近发展的靶向治疗时代，疫苗治疗肾细胞癌的现有知识和未来的作用。
Renal cell carcinoma is the most common malignant tumor originating from the kidney. Compared with other solid tumors, it does not respond to traditional management modalities, such as chemotherapy and radiotherapy. However, it is well known that renal cell carcinoma represents one of the most immune‐responsive cancers and several immunotherapeutic strategies have been investigated in the management of renal cell carcinoma with variable degrees of success. The development of immunotherapy with α‐interferon or high‐dose interleukin‐2 is the best established treatment, and is associated with durable disease control. Although the lack of defined antigens in renal cell carcinoma has hindered more specific vaccine development, research regarding vaccination therapy has been of special interest for the treatment of renal cell carcinoma for more than 30 years. At present, there are three types of cell‐based vaccines in renal cell carcinoma treatment: autologous tumor‐cell vaccines, genetically modified tumor vaccines and dendritic cell‐based vaccines. A further type is peptide‐based vaccination with tumor‐associated antigens as possible targets, such as carbonic anhydrase IX, survivin and telomerase that are overexpressed in renal cell carcinoma. In the present article, we review data from completed clinical trials of vaccine therapy, and discuss future trials to assess the current knowledge and future role of vaccine therapy for renal cell carcinoma in the era of recently developed targeted therapy.